XY03-EA / Shijiazhuang Yiling Pharma - LARVOL DELTA

Research progress of 3-n-butylphthalide and its derivatives in combating cerebral ischemia. (PubMed, Chin J Nat Med) - "Specifically, potassium 2-(1-hydroxypentyl)-benzoate (PHPB), brozopentyl sodium (BZP), and XY-03-EA (ZONK1103) have reached phase II clinical trials, while (S)-2-(1-acetoxypentyl)benzoic acid L-arginine salt (AAPB) has received clinical trial approval for 2024. This review examines the structural modification and optimization of NBP over the past two decades from a medicinal chemistry perspective, aiming to facilitate the development of superior derivatives and advance cerebral ischemia treatment."

Journal • Review • Cardiovascular • CNS Disorders • Ischemic stroke

A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke (clinicaltrials.gov) - P2/3 | N=360 | Enrolling by invitation | Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd

New P2/3 trial • Cardiovascular • Ischemic stroke

A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke (clinicaltrials.gov) - P2 | N=420 | Enrolling by invitation | Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd | Not yet recruiting ➔ Enrolling by invitation | Trial completion date: Aug 2024 ➔ Dec 2023 | Trial primary completion date: Aug 2024 ➔ Dec 2023

Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke

A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke (clinicaltrials.gov) - P2 | N=420 | Not yet recruiting | Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd

New P2 trial • Cardiovascular • Ischemic stroke